Clik here to view.
TCT 2012: New trials and positive results for cardiac implants
Micro Interventional Devices initiates 1st-in-man EU study for its Permaseal News Well, Clinical Trials, Cardiac Implants, Replacement Heart Valves, Research & Development, Stents, Transcatheter...
View ArticleClik here to view.
Volcano gains 7% on legal win over St. Jude Medical as 2nd trial begins
Shares of Volcano Corp. near a 52-week high on their way to gaining 7% on Wall Street, after the medical device company logs a legal win over St. Jude Medical in a patent spat over heart measurement...
View ArticleClik here to view.
Cancer: Delcath lands expanded CE Mark for organ-isolating chemo treatment
Delcath lands expanded CE Mark approval in the European Union to market its targeted chemotherapy delivery system with a drug commonly used to destroy liver tumors. Delcath Systems (NSDQ:DCTH) won...
View ArticleClik here to view.
Weight-loss: Repeat treatments with GI Dynamics' EndoBarrier may extend benefits
Patients re-implanted with GI Dynamics' EndoBarrier weight-loss device experience additional weight-loss and extended improvements in body mass levels and health factors associated with diabetes,...
View ArticleClik here to view.
Masimo CEO Joe Kiani on "Micro Fixing"
Masimo (NSDQ:MASI) Joe Kiani in a July, 2012 TEDx talk discusses his philosophy of "micro-fixing," of how small changes can have larger impact on the world. For a recent MassDevice interview with...
View ArticleClik here to view.
FDA approves InSightec's ultrasound-based ExAblate pain treatment system
Israeli device maker InSightec lands FDA approval to treat painful bone metastases with its ExAblate ultrasound-based therapy. Israeli device maker InSightec won FDA approval for its ExAblate...
View ArticleClik here to view.
Cynosure blows away expectations for 4th consecutive quarter
Wall Street and its analysts bestow some love on Cynosure as the company reports its 4th consecutive expectation-beating quarter. Aesthetics devices maker Cynosure (NSDQ:CYNO) got some Wall Street...
View ArticleCould medical device tax repeal ride along on bigger bill?
Although it's unlikely that the lame-duck U.S. Congress will approve a repeal of the medical device tax this year, but repeal of the 2.3% medtech tax could ride along if key Senate Democrats go along....
View ArticleClik here to view.
Stent wars at TCT 2012: Drug-eluting stents maintain lead over bare-metal
Next-generation drug-eluting stents continue to maintain a lead over their bare-metal cousins as researchers unveil more studies at this week's Transcatheter Cardiovascular Therapeutics meeting. With...
View ArticleClik here to view.
MassDevice.com +3 | The top 3 med-tech stories for October 23, 2012
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the...
View ArticleClik here to view.
Are thinner defibrillator leads more likely to fail? | MassDevice.com On Call
Thinner defibrillator leads, such as those sold and subsequently recalled by Medtronic and St. Jude Medical, are more likely to exhibit failures related to impedance changes and electrical noise,...
View ArticleClik here to view.
New app distills the fine art of interpreting a child's blood pressure
Hypertension is harder to diagnose in children than you think. A new app, which can work with multiple EMR systems, helps doctors interpret a child's blood pressure readings based on age, height, sex...
View ArticleClik here to view.
NuVasive dips despite Street-beating Q3 results
Third-quarter profits for medical device company NuVasive beat Wall Street's expectations, but shares dip nearly 3% anyway on missed sales targets, lowered guidance. keys: Shares of NuVasive Inc....
View ArticleClik here to view.
Bard slides on Q3 results, announces Neomend acquisition
Medical device company C.R. Bard's 3rd-quarter profits dip slightly as it cuts the lower end of its sales guidance and announces the buyout of Neomend, sending shares down nearly 2% today. C.R. Bard...
View ArticleClik here to view.
TCT 2012: Drug-eluting and semi-resorbable stents hold their own
A handful of drug-eluting and semi-resorbable stent studies conclude that new and next-generation stents can hold their own against older staples. Stent makers came out in force for the Transcatheter...
View ArticleClik here to view.
Teleflex closes $276M LMA buyout | Wall Street Beat
Teleflex closes its $276 million acquisition of Singapore-based LMA and its surgical masks business. Teleflex (NYSE:TFX) said it's closed the $276 buyout of surgical mask maker LMA International. The...
View ArticleClik here to view.
Boston Scientific lands updated CE Mark for Promus Element, Promus Element...
Medical device company Boston Scientific wins European regulatory approval to update the labels on its Promus Element and Promus Element Plus coronary stents to include 3-month DAPT therapy. Medical...
View ArticleClik here to view.
Abiomed touts positive results for its Symphony heart pump
Abiomed unveils clinical updates on its Symphony device following the 2nd successful human use in Canada, showing positive results over 28 days. Massachusetts medical device company Abiomed...
View ArticleClik here to view.
Report: Medtech spending, pricing barely budged in more than 20 years
Medical device spending as a portion of U.S. national health expenditures increased less than 1% over the last 2 decades, according to AdvaMed's updated report. Click to enlarge graph. Medical devices...
View ArticleClik here to view.
TCT 2012 UPDATE: St. Jude Medical ticks up on positive PressureWire data
A study funded by St. Jude Medical shows that its PressureWire fractional flow reserve technology is cheaper over the long run that optimal medical therapy, sending STJ shares up slightly today....
View Article
